865626-97-7

Upstream product

• 206558-34-1 C₁₅H₁₉NO₂ 
• 247259-33-2 methyl 2-(1-benzylpiperidin-4-yl)acetate 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 865626-96-6 (±)-methyl 2-(1-benzylpiperidin-4-yl)-3-hydroxy-3-(2-nitrophenyl)propanoate 

Downstream Products

• 912463-38-8 4-nitrophenyl 4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxylate 
• 1458062-06-0 (±)-1-(7-benzyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazin-3-yl)-2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)ethyl 4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxylate 
• 1458062-08-2 (±)-1-(7-benzyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazin-3-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl 4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxylate 

Relevant academic research and scientific papers

TETRAHYDROIMDIDAZOPYRAZINE DERIVATIVES AS CGRP RECEPTOR ANTAGONISTS

The disclosure generally relates to the novel compounds of formula I, including pharmaceutically acceptable salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the t

CGRP antagonists

The present invention encompasses compounds of Formula I which are antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and t

Novel therapeutic agents for the treatment of migraine

The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their u